Fuzheng huayu Pian(FZHY)

Fuzheng huayu Pill has been shown to significantly improve liver function and clinical symptoms, decrease collagen synthesis, promote degradation of extracellular matrix, reverse hepatic fibrosis, and reduce mental stress in patients with chronic hepatitis B and liver cirrhosis.

Functions

Promoting blood circulation to remove blood stasis,replenishing vital essnce to nourish liver.

Indications

For hepatitis B liver fibrosis (caused by blood stasis blocking collaterals,liver and kidney deficiency).

Spec

0.4g*48 pills/unit

Dosage

Take Orally,4 pils per time,thrice daily,24 weeks as a treatment course.

About Packages

Experience package including 21 bottles with 1008 pills which may last 84 days.

1 course package including 42 bottles with 2016 pills which may last 168 days.

The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability -----[link]

Results

40 active ingredients in Fuzheng huayu capsule formula and their 79 potential target proteins were identified by network pharmacology approach. Further network analysis reduced the 79 potential target proteins to 31, which were considered more likely to be the target proteins of the active components in Fuzheng huayu capsule formula. In addition, further enrichment analysis of 31 target proteins indicated that the HIF-1, PI3K-Akt, FoxO, and chemokine signaling pathways may be the primary pathways regulated by Fuzheng huayu capsule formula in inhibiting the HSCs viability for the treatment of liver fibrosis. Of the 31 target proteins, peroxisome proliferator activator receptor gamma (PPARG) was selected for validation by experiments at the cellular and molecular level. The results demonstrated that schisandrin B, salvianolic acid A and kaempferol could directly bind to PPARG, decreasing the viability of HSCs (T6 cells and LX-2 cells) and exerting anti-fibrosis effects.

Conclusion

The active ingredients of Fuzheng huayu capsule formula were successfully identified and the mechanisms by which they inhibit HSC viability determined, using network pharmacology and transcriptomics. This work is expected to benefit the clinical application of this formula.

PHARMACOLOGIC ACTION

Pharmacological tests show that this product can inhibit the liver fibrosis process of carbon tetrachloride and lipid-rich diet-induced in rats, inhibition of carbon tetrachloride and D-galactosamine induced serum alanine aminotransferase increased. Long-term toxicity tests show that the product of continuous gavage administration of 6 months in rats, 2.30,0.37g / Kg rats can reduce the number of reticulocytes in rats and increase the number of white blood cells.

ADVERSE REACTION

Occasionally appears discomfort in the stomach.